These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17643275)

  • 21. Trastuzumab in breast cancer.
    Mastrianni DM
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470953
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical practice guidelines for breast cancer rehabilitation: syntheses of guideline recommendations and qualitative appraisals.
    Harris SR; Schmitz KH; Campbell KL; McNeely ML
    Cancer; 2012 Apr; 118(8 Suppl):2312-24. PubMed ID: 22488705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical practice guidelines.
    Twaddle S
    Singapore Med J; 2005 Dec; 46(12):681-6; quiz 687. PubMed ID: 16308640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
    Poncet B; Colin C; Bachelot T; Jaisson-Hot I; Derain L; Magaud L; Fournel-Federico C; Mousseau M; Tigaud JD; Jacquin JP; Trillet-Lenoir V
    Am J Clin Oncol; 2009 Aug; 32(4):369-74. PubMed ID: 19381078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).
    Grunfeld E; Dhesy-Thind S; Levine M;
    CMAJ; 2005 May; 172(10):1319-20. PubMed ID: 15883407
    [No Abstract]   [Full Text] [Related]  

  • 28. Human epidermal growth factor receptor 2 testing: where are we?
    De P; Smith BR; Leyland-Jones B
    J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
    [No Abstract]   [Full Text] [Related]  

  • 29. Scottish Intercollegiate Guidelines Network (SIGN) 87--the management of oesophageal and gastric cancer.
    Alderson D
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):530-1. PubMed ID: 18538556
    [No Abstract]   [Full Text] [Related]  

  • 30. Neutrophil elastase predicts trastuzumab responsiveness in metastatic breast cancer.
    Yamashita J; Akizuki M; Jotsuka T; Harao M; Nakano S
    Breast J; 2006; 12(3):288. PubMed ID: 16684339
    [No Abstract]   [Full Text] [Related]  

  • 31. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 32. First MAb approved for treatment of metastatic breast cancer.
    Brenner TL; Adams VR
    J Am Pharm Assoc (Wash); 1999; 39(2):236-8. PubMed ID: 10079656
    [No Abstract]   [Full Text] [Related]  

  • 33. Unusual problems in breast cancer and a rare lung cancer case. Case 1. Clinical complete response of breast cancer metastases after trastuzumab-based immunotherapy.
    Tonini G; Vincenzi B; Santini D; Avvisati G; La Cesa A; Baldi A
    J Clin Oncol; 2003 Jun; 21(11):2215-6. PubMed ID: 12775749
    [No Abstract]   [Full Text] [Related]  

  • 34. Implementing evidence-based health care: the nurse teachers' role in supporting the dissemination and implementation of SIGN clinical guidelines.
    Thomson P
    Nurse Educ Today; 2000 Apr; 20(3):207-17. PubMed ID: 10820575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
    Ferretti G; Fabi A; Felici A; Papaldo P
    J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
    [No Abstract]   [Full Text] [Related]  

  • 37. Adjuvant trastuzumab for breast cancer.
    Dent R; Clemons M
    BMJ; 2005 Nov; 331(7524):1035-6. PubMed ID: 16269471
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant trastuzumab for breast cancer: advent of pharmacogenetics raises many issues.
    Thornton H
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293848
    [No Abstract]   [Full Text] [Related]  

  • 39. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
    Fong A; Shafiq J; Saunders C; Thompson A; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
    Breast; 2012 Aug; 21(4):562-9. PubMed ID: 22297168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New breast cancer drug.
    Harv Womens Health Watch; 1998 Nov; 6(3):7. PubMed ID: 9814134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.